SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP) -- Ignore unavailable to you. Want to Upgrade?

To: Bob Schommer who wrote (1431)3/16/2000 1:20:00 PM
From: Sean Janzen  Read Replies (2) | Respond to of 1501
 
Bob,

I am employing a similar investment style with IZP. Those of us that have been in IZP 4-5 years know the joy and the pain of being long. I remember when IZP traded at $0.20 Canadian.

Goldman Sachs / Rothschild had to wait 2 years to see the share price recover to their original investment price of $1.90.

Those days are gone. It is my opinion that if IZP management is successful with its business plan then the stock could trade $20-$40 in the next few years.

Don Wolanchuk, market timer of the year for 14 years running, uses a similar investment style with great success.

Biotechnology Investments Ltd. pick up a few shares:

stockhouse.com



To: Bob Schommer who wrote (1431)3/16/2000 5:40:00 PM
From: SG  Read Replies (2) | Respond to of 1501
 
Well, I initially bot this co. in hopes it would find a Crohn's cure for my son. That's not going to happen soon. I then decided it had other good products in the pipeline. It is tuff watching $$ go down the drain; am trying to keep a long term perspective (In the long run..we're all dead. ?Milton Friedman-forget who.)

SG


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News